Edition:
United States

Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

96.22EUR
11:35am EDT
Change (% chg)

€1.91 (+2.03%)
Prev Close
€94.31
Open
€94.99
Day's High
€96.50
Day's Low
€94.90
Volume
2,932,810
Avg. Vol
2,788,716
52-wk High
€137.80
52-wk Low
€83.45

BAYGn.DE

Chart for BAYGn.DE

About

Bayer AG is a life science company. The Company's segments are Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment is engaged in the development of prescription pharmaceuticals; contraceptives, and medical products, such as injection systems and contrast agents for diagnostic... (more)

Overall

Beta: 0.94
Market Cap(Mil.): €77,989.45
Shares Outstanding(Mil.): 826.95
Dividend: 2.50
Yield (%): 2.65

Financials

  BAYGn.DE Industry Sector
P/E (TTM): 18.51 39.19 39.69
EPS (TTM): 5.09 -- --
ROI: 7.46 15.23 14.44
ROE: 18.56 16.16 15.49

Judge rules against nearly 1,300 lawsuits over Bayer's Mirena IUD

NEW YORK A New York federal judge has ruled in favor of Bayer AG against nearly 1,300 lawsuits filed by women who say they suffered internal injuries from the company's Mirena intra-uterine contraceptive device.

Jul 28 2016

Judge rules against nearly 1,300 lawsuits over Bayer's Mirena IUD

NEW YORK A New York federal judge has ruled in favor of Bayer AG against nearly 1,300 lawsuits filed by women who say they suffered internal injuries from the company's Mirena intra-uterine contraceptive device.

Jul 28 2016

UPDATE 2-Judge rules against nearly 1,300 lawsuits over Bayer's Mirena IUD

NEW YORK, July 28 A New York federal judge has ruled in favor of Bayer AG against nearly 1,300 lawsuits filed by women who say they suffered internal injuries from the company's Mirena intra-uterine contraceptive device.

Jul 28 2016

Judge rules against some 1,300 lawsuits over Bayer's Mirena IUD

July 28 A New York federal judge has ruled in favor of Bayer AG against nearly 1,300 lawsuits filed by women who say they suffered internal injuries from the company's Mirena intra-uterine contraceptive device.

Jul 28 2016

BRIEF-Bayer CFO says no need to rush into Covestro share sale

* CFO Johannes Dietsch says no need to rush into any Covestro share sale transaction, no need to pile up further cash at the moment

Jul 27 2016

Bayer drugs secure earnings beat, offset weak crop chems

FRANKFURT Bayer , the German drugmaker trying to acquire U.S. seed company Monsanto , surpassed second-quarter earnings expectations and raised its guidance for the year as strong gains in stroke prevention pill Xarelto offset sluggish farming pesticides markets.

Jul 27 2016

UPDATE 1-Bayer drugs secure earnings beat, offset weak crop chems

* Shares seen up 0.7 pct in premarket trades (Adds details on Xarelto, Eylea, Crop Chemicals unit, background on Monsanto)

Jul 27 2016

Bayer's drugs unit secures Q2 earnings beat

FRANKFURT, July 27 Bayer, the German drugmaker trying to acquire U.S. seed company Monsanto, easily surpassed second-quarter earnings expectations and raised its full-year guidance on strong gains in stroke prevention pill Xarelto and anti-blindness drug Eylea.

Jul 27 2016

Plaintiffs seek MDL for Bayer Essure cases

Plaintiffs' lawyers have asked a federal judicial panel to create a new multidistrict litigation for a growing number of cases alleging Bayer's Essure contraceptive device can cause debilitating injuries.

Jul 25 2016

Monsanto rejects Bayer's sweetened offer, open to talks

U.S. seed company Monsanto Co turned down a sweetened $64 billion acquisition offer from Bayer AG , but said it was open to further talks with the German healthcare and chemicals group as well as other parties.

Jul 19 2016

Earnings vs. Estimates